Tranilast directly targets NLRP3 to treat inflammasome-driven diseases.
Tranilast directly targets NLRP3 to treat inflammasome-driven diseases.
复制标题
曲尼司特直接靶向 NLRP3 治疗炎症小体驱动的疾病
DOI:
10.15252/emmm.201708689
复制
发表时间:
2018-04
影响因子:
11.1
通讯作者:
Zhou R
中科院分区:
文献类型:
--
作者:
Huang Y;Jiang H;Chen Y;Wang X;Yang Y;Tao J;Deng X;Liang G;Zhang H;Jiang W;Zhou R
The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is a direct NLRP3 inhibitor. TR inhibits NLRP3 inflammasome activation in macrophages, but has no effects on AIM2 or NLRC4 inflammasome activation. Mechanismly, TR directly binds to the NACHT domain of NLRP3 and suppresses the assembly of NLRP3 inflammasome by blocking NLRP3 oligomerization. In vivo experiments show that TR has remarkable preventive or therapeutic effects on the mouse models of NLRP3 inflammasome‐related human diseases, including gouty arthritis, cryopyrin‐associated autoinflammatory syndromes, and type 2 diabetes. Furthermore, TR is active ex vivo for synovial fluid mononuclear cells from patients with gout. Thus, our study identifies the old drug TR as a direct NLRP3 inhibitor and provides a potentially practical pharmacological approach for treating NLRP3‐driven diseases.
登录
查看更多内容
影响因子:
29.7
作者:
Davis BK;Wen H;Ting JP
通讯作者:
Ting JP
影响因子:
16.6
作者:
Daniels MJ;Rivers-Auty J;Schilling T;Spencer NG;Watremez W;Fasolino V;Booth SJ;White CS;Baldwin AG;Freeman S;Wong R;Latta C;Yu S;Jackson J;Fischer N;Koziel V;Pillot T;Bagnall J;Allan SM;Paszek P;Galea J;Harte MK;Eder C;Lawrence CB;Brough D
通讯作者:
Brough D
影响因子:
64.8
作者:
通讯作者:
--
DOI:
10.1073/pnas.0611496104
发表时间:
2007-05-08
影响因子:
11.1
作者:
Duncan, Joseph A.;Bergstralht, Daniel T.;Ting, Jenny Pan-Yun
通讯作者:
Ting, Jenny Pan-Yun
影响因子:
7.3
作者:
AZUMA, H;BANNO, K;YOSHIMURA, T
通讯作者:
YOSHIMURA, T